| CAS NO: | 177943-33-8 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 177943-33-8 |
| Canonical SMILES | ON1C2=CC=CC=C2C[C@@H](C1=O)N.Cl |
| 分子式 | C9H10N2O2.HCl |
| 分子量 | 214.7 |
| 溶解度 | DMSO: 22 mg/ml,Water: 22 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | PF-04859989 is an inhibitor of kynurenine aminotransferase II (KAT II; IC50s = 0.032 and 0.263 µM for human and rat recombinant enzymes, respectively).1It is selective for KAT II over KAT I, -III, and -IV (IC50s = 21.6, 107, and >50 µM, respectively).In vivo, PF-04859989 (10 mg/kg, s.c.) reduces basal striatum, prefrontal cortex, and hippocampus kynurenic acid levels in rats. It prevents ketamine- or amphetamine-induced disruption of auditory gating in rats, as well as prevents ketamine-induced deficits in spatial memory in non-human primates. PF-04859989 also inhibits glutamate oxaloacetate transaminase 1 (GOT1; IC50= 8 µM) and reduces the viability of PaTu 8988t and PaTu 8902 pancreatic cancer cells in a concentration-dependent manner.2 1.Kozak, R., Campbell, B.M., Strick, C.A., et al.Reduction of brain kynurenic acid improves cognitive functionJ. Neurosci.34(32)10592-10602(2014) 2.Yoshida, T., Yamasaki, S., Kaneko, O., et al.A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growthBiochem. Biophys. Res. Commun.522(3)633-638(2020) |
m.cnreagent.com